- No public price. Per-test pricing is not published.
- Not disclosed
- Not disclosed
- —
- —
- NO
Pathology
DoMore Diagnostics
by DoMore Diagnostics · NO
Histotype Px Colorectal predicts outcome in stage II and III colorectal cancer from standard H&E slides. CE-IVD marked in 2022.
On this page
5/100Tracked
- Regulatory & Compliance0/28
No FDA clearance listed
- Clinical Integration0/26
No EHR integrations listed
- Evidence Strength0/28.8
No peer-reviewed coverage
- Vendor & Market3/18
Seed-stage or unfunded
- Sentiment & Transparency2.5/14
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance0/18
No FDA clearance listed
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/14
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/8
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers0/21
No peer-reviewed coverage
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal3/12
Seed-stage or unfunded
- Years in market0/6
Founded year not recorded
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/5
Pricing on request, no public amounts
Histotype Px Colorectal predicts outcome in stage II and III colorectal cancer from standard H&E slides. CE-IVD marked in 2022.
No public price. Per-test pricing is not published.
Bottom line
DoMore Diagnostics is an Oslo company whose product is Histotype Px Colorectal, an AI test that estimates outcome in stage II and III colorectal cancer from a routine H&E slide. It carries a CE-IVD mark in Europe, and the company calls it research use only outside the EU. The FDA's 510(k) records list nothing for DoMore. Funding comes from an EIC Accelerator award and Norwegian research grants, and no per-test price is published.
What does Histotype Px Colorectal do?
The homepage promises "Personalized Cancer Treatment Delivered with AI" and says the aim is to reduce over- and undertreatment in cancer through digital pathology. The product reads an H&E whole-slide image of a stage II or III colorectal adenocarcinoma and sorts the patient into low, intermediate or high risk. That risk group is meant to inform whether adjuvant chemotherapy is worth giving, according to the company's news. The pipeline also includes a minimal residual disease biomarker.
What is the regulatory status?
The CE-IVD mark was announced on 31 May 2022 under the old IVDD directive, per Tissue Pathology. The same announcement says the test is research use only outside the EU, which is the company's wording.
In the US, the FDA's 510(k) records list no clearance under DoMore or Do More Diagnostics, so a US oncology practice has no cleared version to order.
What validation is under way?
DoMore announced a clinical collaboration with FFCD and CHU Dijon in France in December 2025, and presented a US cohort validation at ESMO AI & Digital Oncology 2025. Both are company-reported.
Who is behind it, and who pays?
DoMore is based in Oslo. It grew out of work at Oslo University Hospital, Oxford University and University College London, and the Health AI Register gives 2020 as the founding year. The company won an EIC Accelerator award in February 2024 worth up to EUR 10 million, made of a EUR 2.5 million grant and up to EUR 7.5 million in equity from the EIC Fund. Norway's Research Council gave NOK 16 million in December 2023 for clinical validation and a second NOK 16 million for the MRD biomarker project.
How is the test priced?
DoMore publishes no per-test price.
Who would order it?
A European oncology service that wants a risk estimate in stage II and III colon cancer as an input to the adjuvant chemotherapy decision.
The verdict
Histotype Px Colorectal fits a European oncology service that wants a CE-IVD risk group for stage II and III colorectal cancer. A US practice cannot order it as a cleared test, and a service outside the EU would be using it for research only on the company's own labelling. The French collaboration and the US cohort validation are announcements so far.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Quote only | — | — | No public price. Per-test pricing is not published. |
Source: vendor pricing page. Last checked October 15, 2026.
What deploys cleanly
Carries CE-IVD (Histotype Px Colorectal, May 2022) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.
Other pathology
See the full pathology ranking
Tempus Digital Pathology
by Tempus AI
Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.
No public price on the Tempus pages.|FDA De Novo (DEN200080) / FDA 510(k) (FullFocus viewer)
PathAI AISight
by PathAI
Cloud image management for digital pathology with AISight Dx, cleared for primary diagnosis, plus biopharma AI services.
No public price. Billing period, trial and refund not stated.|FDA 510(k)
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
No public price. Demo request only.|FDA 510(k) / SOC 2 Type II (vendor announcement, 2025-12-03)
Ibex Medical Analytics
by Ibex
AI pathology software for prostate, breast and gastric cancer. One US FDA 510(k) clearance, for prostate.
No public price. Sold to laboratories and health systems on enterprise contracts.|FDA 510(k)